Wellington Management Group’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
Other funds holding MNPR
SVCM
SL
Wellington Management Group's MNPR Position: Q3 2026 in Review
Wellington Management Group increased its Monopar Therapeutics (MNPR) stake by 9.6% in Q3 2026, buying an estimated $1.63M and bringing the position to 173,645 shares worth $13.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1160.
Wellington Management Group first reported a position in MNPR in Q3 2025 and has held it in 5 quarters since. The position peaked at $18.9M in Q3 2025. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.
- Wellington Management Group held 173,645 shares of Monopar Therapeutics worth $13.8M as of Q3 2026.
- Wellington Management Group bought 15,208 Monopar Therapeutics shares in Q3 2026, an estimated $1.63M.
- Monopar Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q3 2026, its #1160 holding.
- Wellington Management Group first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Wellington Management Group's Monopar Therapeutics position peaked at $18.9M in Q3 2025.
- 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.
Based on Wellington Management Group's 13F filing for Q3 2026, filed 16 Nov 2026.